Since 1996 WHN is the second oldest medical website on the net, second only to the American Medical Association, servicing over 35,000 physicians and scientists worldwide.
Non-Profit Trusted Source of Non-Commercial Health Information
These are the findings of a new analysis of brain scans from close to 60 people receiving treatment for depression, led by Imperial College London’s Centre for Psychedelic Research. The team behind the study believes it may have untangled how psilocybin exerts its therapeutic effects on the brain. Psilocybin is one of a number of …
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for …
London based biotech Compass Pathways has successfully raised $80 million to bring its psilocybin therapy towards phase 3 development and prepare for trials; the drug is the active ingredient in magic mushrooms and it is being advanced for possible investigation of use in those with treatment resistant depression. Psilocybin has been studied in the past …
Magic mushrooms are fungi that contains the active compound psilocybin, which is a known hallucinogen that affects the part of the brain responsible for cognition, perception, and mood; psilocybin is being investigated for the effects on mental health and the possible potential to address various mental health conditions. These are wild mushrooms that can be …